Structure-based machine learning screening identifies natural product candidates as potential geroprotectors.

Area of Science:

• Gerontology and Pharmacology
• Biomedical Engineering and Computational Biology

Background:

• Age-related diseases pose significant global health challenges, impacting quality of life and healthcare systems.
• Pharmacological interventions, including geroprotectors, are being explored to mitigate aging's adverse effects.
• Geroprotectors aim to maintain homeostasis by targeting hallmarks of aging.

Purpose of the Study:

• To explore the potential of geroprotectors in combating age-related decline.
• To investigate the role of machine learning (ML) in accelerating the identification and design of geroprotective compounds.

Main Methods:

• Review of current research on geroprotectors and their mechanisms.
• Exploration of machine learning applications in drug discovery and development.
• Analysis of how ML can optimize the identification of novel geroprotective molecules.

Main Results:

• Geroprotectors show promise in targeting specific aging pathways.
• Machine learning significantly enhances the speed and efficiency of drug design.
• ML models can predict potential geroprotective compounds with greater accuracy.

Conclusions:

• Geroprotectors represent a promising therapeutic strategy for age-related diseases.
• Machine learning is a transformative tool for developing novel geroprotective drugs.
• Integrating ML into drug discovery pipelines can expedite the development of interventions to promote healthy aging.